Humanized antibodies that recognize alpha-synuclein

Patent metadata

Field	Value
Publication number	US-9884906-B2
Application number	US-201615387580-A
Country	US
Kind code	B2
Filing date	Dec 21, 2016
Priority date	Oct 28, 2011
Publication date	Feb 6, 2018
Grant date	Feb 6, 2018

Abstract

The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.

First claim

What is claimed is:

1. A nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region of an antibody that specifically binds to human alpha synuclein, wherein the mature heavy variable region comprises the three Kabat CDRs of SEQ ID NO:11, and is at least 90% identical to SEQ ID NO:11, and wherein the mature light chain variable region comprises the three Kabat CDRs of SEQ ID NO:4, and is at least 90% identical to SEQ ID NO:4.

2. The nucleic acid of claim 1 having a sequence comprising any one of SEQ ID NO:15, 17, 18, 19, and 20.

3. A host cell comprising a vector comprising the nucleic acid of claim or 2.

4. A method of producing an antibody, comprising culturing cells transformed with a nucleic acid or nucleic acids encoding the heavy and light chains of the antibody of claim 1 , so that the cell secrete the antibody; and purifying the antibody from cell culture media.

5. A method of producing a cell line producing an antibody, comprising introducing a vector encoding heavy and light chains of an antibody of claim 1 and a selectable marker into cells; propagating the cells under conditions to select for cells having increased copy number of the vector; isolating single cells from the selected cell; and banking cells cloned from a single cell selected based on yield of antibody.

6. The method of claim 5 , further comprising propagating the cells under selective conditions and screening for cell lines naturally expressing and secreting at least 100 mg/L/10 6 cells/24 h.

7. The nucleic acid of claim 1 , wherein the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 11 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:4 except provided that position L36(Kabat numbering) can be occupied by Y or F, position L83 (Kabat numbering) can be occupied by F or L, position H73 (Kabat numbering) can be occupied by N or D and position H93 (Kabat numbering) can be occupied by A or S.

8. The nucleic acid of claim 1 , wherein position H73 (Kabat numbering) is occupied by D, position H93 (Kabat numbering) is occupied by A, position L36 (Kabat numbering) is occupied by F, and position L83 (Kabat numbering) is occupied by L.

9. The nucleic acid of claim 1 , wherein the mature heavy chain variable region is at least 95% identical to SEQ ID NO:10 and mature light chain variable region is at least 95% identical to SEQ ID NO:5.

10. The nucleic acid of claim 1 , wherein the mature heavy chain variable region has an amino acid sequence at least 98% identical to SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence at least 98% identical to SEQ ID NO:5.

11. The polynucleotide of claim 1 , wherein the mature heavy chain variable region has an amino acid sequence at least 99% identical to SEQ ID NO: 10 and the mature light chain variable region has an amino acid sequence at least 99% identical to SEQ ID NO:5.

12. The nucleic acid of claim 1 , wherein the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:10 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:5.

13. The nucleic acid of claim 1 , wherein the mature variable light chain has the amino acid sequence of SEQ ID NO:3, 4 or 5 and the mature variable heavy chain has the amino acid sequence of SEQ ID NO:8, 9 or 10.

14. The nucleic acid claim 1 , wherein the nucleic acid encodes the mature heavy chain variable region fused to a heavy chain constant region having the amino acid sequence of SEQ ID NO:32.

15. The nucleic acid of claim 1 , wherein the nucleic acid encodes the mature light chain variable region fused to a light chain constant region having the amino acid sequence of SEQ ID NO:13.

16. The nucleic acid of claim 1 , wherein the nucleic acid encodes the mature heavy chain variable region fused to a heavy chain constant region having the amino acid sequence of SEQ ID NO:32 and the mature light chain variable region fused to a light chain constant region having the amino acid sequence of SEQ ID NO:13.

17. The nucleic acid of claim 1 , wherein the nucleic acid encodes the mature light chain variable region as a component of a light chain having the amino acid sequence of SEQ ID NO 29.

18. The nucleic acid of claim 1 , wherein the nucleic acid encodes the mature light chain variable region as a component of a light chain having the amino acid sequence of SEQ ID NO:30.

19. The nucleic acid of claim 1 , wherein the nucleic acid encodes the mature heavy chain variable region as a component of a heavy chain having the amino acid sequence of SEQ ID NO:31.

20. The nucleic acid of claim 1 having a sequence comprising SEQ ID NO:20 encoding the mature heavy chain and SEQ ID NO:17 encoding the mature light chain.

Assignees

• Prothena Biosciences Ltd

Inventors

• Saldanha Jose William
• Nijjar Tarlochan S

Classifications

• A61K39/00 Primary

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title